Acebutolol

Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

Europe

Belgium: Acebutolol, Sectral; Czech Republic: Acebutolol, Acecor, Apo-Acebutol, Sectral; Denmark: Diasectral; Finland: Diasectral, Espesil; France: Acebutolol, Sectral; Germany: Acebutolol, Prent, Tredalat; Italy: Prent, Sectral; Luxembourg: Acebutolol, Sectral; Netherlands: Acebutolol, Sectral; Poland: Abutol, Acebutolol, Acecor, Sectral; Portugal: Prent; Slovakia: Acecor; UK: Acebutolol, Sectral.

North America

Canada: Acebutolol, Rhotral, Sectral; USA: Acebutolol, Sectral.

Asia

Japan: Acebutolol, Acetanol, Sectral.

Drug combinations

Acebutolol and Hydrochlorothiazide

Acebutolol and Nifedipine

Chemistry

Acebutolol: C~18~H~28~N~2~O~4~. Mw: 336.43. (1) Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-, (±)-; (2)(±)-3′-Acetyl-4′-[2-hydroxy-3-(isopropylamino)propoxy]butyranilide. CAS-37517-30-9 (1973).

Acebutolol Hydrochloride: C~18~H~28~N~2~O~4~ HCl. Mw: 372.89. (±)-3′-Acetyl-4′-[2-hydroxy-3-(isopropylamino)propoxy]butyranilide monohydrochloride. CAS-34381-68-5.

Pharmacologic Category

Class II Antiarrhythmic Agents; β-Adrenergic Blocking Agents (Intrinsic Sympathomimetic Activity). (ATC-Code: C07AB04).

Mechanism of action

Competitively blocks β~1~-adrenergic receptors with little or no effect on β~2~-receptors, except at high doses. Membrane-stabilizing and intrinsic sympathomimetic activity.

Therapeutic use

Treatment of hypertension. Management of ventricular arrhythmias.

Pregnancy and lactiation implications

Acebutolol and its metabolite cross the human placenta. β-Blockers are generally safe during pregnancy. Use not recommended during lactation.

Unlabeled use

Treatment of chronic stable angina.

Contraindications

Overt cardiac failure. Cardiogenic shock. Persistently-severe bradycardia or second- and third-degree heart block (except in patients with a functioning artificial pacemaker).

Warnings and precautions

Anaphylactic reactions (use caution in history of severe anaphylaxis to allergens). Avoid use in bronchospastic disease and in heart failure. Caution in the following cases: diabetes mellitus (may potentiate hypoglycemia and/or mask signs and symptoms), hepatic and renal impairment, mesenteric or peripheral vascular disease (may precipitate or aggravate symptoms of arterial insufficiency), myasthenia gravis, psychiatric illness (may cause or exacerbate CNS depression), Raynaud’s disease (may precipitate symptoms), pheochromocytoma, or thyrotoxicosis (may mask signs of hyperthyroidism). Should not be withdrawn abruptly (may cause acute tachycardia and hypertension).

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart